The oncology drugs market size was valued at $135,494.17 million in 2020, and is projected to reach $274,400.63 million by 2030, registering a CAGR of 7.5% from 2021 to 2030. Cancer is caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.
List of Key Players
- ABBVIE INC.
- AMGEN, INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB COMPANY
- F. HOFFMANN-LA ROCHE AG
- JOHNSON & JOHNSON
- MERCK & CO., INC.
- NOVARTIS INTERNATIONAL AG
- PFIZER, INC.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/121
Key Findings Of The Study
- On the basis of drug class type, the targeted therapy segment held largest oncology drugs market share in 2020, and is expected to remain dominant throughout the forecast period.
- On the basis of indication, the breast cancer segment held largest market share in 2020 and is expected to remain dominant throughout the forecast period.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
For Purchase inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/121
By drug class type, targeted therapy segment is anticipated to grow with the largest share throughout the forecast period. This is attributed to the identification of molecular targets of cancer cells, fewer adverse effects, and availability of number of targeted therapeutics. Recent advances in cellular technology have contributed to improve the understanding of tumor cells and their metabolism at molecular level, thus driving the need for targeted drug therapies for cancer treatment. On the other side, the demand for immunotherapy is projected to exhibit the fastest market growth during the forecast period due to its affectivity, and expected launch of pipeline immunotherapies.
By indication, breast cancer segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, due to increase in number of females suffering from breast cancer. In addition, adoption of unhealthy lifestyle, increasing female geriatric population, exposure to harmful radiation and increasing governmental initiatives also contributed toward the growth of the oncology drugs market. On the other side lung cancer is projected to exhibit the fastest market growth during the forecast period, owing to higher incidence, increase in geriatric population, changes in lifestyle of people, and rise in smoking of tobacco that includes passive smoking, which may lead to lung cancer.
North America accounted for the largest share of revenue in 2020, and is anticipated to maintain its dominance from 2021 to 2030, owing to presence of large patient population, strong presence of key players, ease of drug availability, well developed healthcare infrastructure, favorable reimbursement policies in healthcare system, higher number of research, development, & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to witness growth at the highest CAGR, owing to increase in number of cancer affected population and rise in awareness related to different cancers.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
firstname.lastname@example.orgTags:Reportedtimes, Financial Content, PR-Wirein, Research Newswire, English